Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, Steinskog ESS, Blix ES, Flobak Å, Oppedal IA, Meltzer S, Torkildsen CF, Blakstad H, Lindemann K, Smeland S, Amundsen A, Taskén K, Helland Å, InPred Consortium (2026)
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial
Acta Oncol, 65, 90-96
DOI 10.2340/1651-226X.2026.45086, PubMed 41664938

Solli E, Bevilacqua A, Wenes M, Migliorini D, van der Veen L, Skånland SS, Di Conza G, Taskén K (2026)
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity
Mol Oncol (in press)
DOI 10.1002/1878-0261.70203, PubMed 41568714

Van der Pol H, Kringelbach T, Martin Agudo M, Bratseth Stav G, Fagereng GL, Fiocco M, Sørum Falk R, Homer V, Haj Mohammad S, Timmer H, Verlingue L, Helland Å, Rohrberg K, Lassen U, Halford S, Jalkanen K, Juslin T, Krebs MG, Oliveira J, Baltruskeviciene E, Ojamaa K, Taskén K, Gelderblom H (2026)
Procedures of data merging in precision cancer medicine: the PRIME-ROSE project
Acta Oncol, 65, 1-8
DOI 10.2340/1651-226X.2026.44889, PubMed 41496458